Prioritizing drug targets in Clostridium botulinum with a computational systems biology approach.

A computational and in silico system level framework was developed to identify and prioritize the antibacterial drug targets in Clostridium botulinum (Clb), the causative agent of flaccid paralysis in humans that can be fatal in 5 to 10% of cases. This disease is difficult to control due to the emergence of drug-resistant pathogenic strains and the only available treatment antitoxin which can target the neurotoxin at the extracellular level and cannot reverse the paralysis. This study framework is based on comprehensive systems-scale analysis of genomic sequence homology and phylogenetic relationships among Clostridium, other infectious bacteria, host and human gut flora. First, the entire 2628-annotated genes of this bacterial genome were categorized into essential, non-essential and virulence genes. The results obtained showed that 39% of essential proteins that functionally interact with virulence proteins were identified, which could be a key to new interventions that may kill the bacteria and minimize the host damage caused by the virulence factors. Second, a comprehensive comparative COGs and blast sequence analysis of these proteins and host proteins to minimize the risks of side effects was carried out. This revealed that 47% of a set of C. botulinum proteins were evolutionary related with Homo sapiens proteins to sort out the non-human homologs. Third, orthology analysis with other infectious bacteria to assess broad-spectrum effects was executed and COGs were mostly found in Clostridia, Bacilli (Firmicutes), and in alpha and beta Proteobacteria. Fourth, a comparative phylogenetic analysis was performed with human microbiota to filter out drug targets that may also affect human gut flora. This reduced the list of candidate proteins down to 131. Finally, the role of these putative drug targets in clostridial biological pathways was studied while subcellular localization of these candidate proteins in bacterial cellular system exhibited that 68% of the proteins were located in the cytoplasm, out of which 6% was virulent. Finally, this framework may serve as a general computational strategy for future drug target identification in infectious diseases.

[1]  M. Nei.  Molecular Evolutionary Genetics , 1987 .

[2]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[3]  Kalidas Yeturu,et al.  targetTB: A target identification pipeline for Mycobacterium tuberculosis through an interactome, reactome and genome-scale structural analysis , 2008, BMC Systems Biology.

[4]  A. T. Carter,et al.  Genome sequence of a proteolytic (Group I) Clostridium botulinum strain Hall A and comparative analysis of the clostridial genomes. , 2007, Genome research.

[5]  J. Hugot.  Inflammatory bowel disease: a complex group of genetic disorders. , 2004, Best practice & research. Clinical gastroenterology.

[6]  D. Swerdlow,et al.  Botulism in the United States: A Clinical and Epidemiologic Review , 1998, Annals of Internal Medicine.

[7]  Corey Nislow,et al.  Recent advances and method development for drug target identification. , 2010, Trends in pharmacological sciences.

[8]  Christopher T. Walsh,et al.  Antibiotics for Emerging Pathogens , 2009, Science.

[9]  Damian Szklarczyk,et al.  The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..

[10]  M. Pucci.  Use of genomics to select antibacterial targets. , 2006, Biochemical pharmacology.

[11]  Vicki Stone,et al.  An in vitro assessment of panel of engineered nanomaterials using a human renal cell line: cytotoxicity, pro-inflammatory response, oxidative stress and genotoxicity , 2013, BMC Nephrology.

[12]  K. Inoue,et al.  botR/A is a positive regulator of botulinum neurotoxin and associated non‐toxin protein genes in Clostridium botulinum A , 1998, Molecular microbiology.

[13]  Zhiyong Lu,et al.  Predicting subcellular localization of proteins using machine-learned classifiers , 2004, Bioinform..

[14]  David S Wishart,et al.  Computational systems biology in drug discovery and development: methods and applications. , 2007, Drug discovery today.

[15]  C. Prober,et al.  Principles and Practice of Pediatric Infectious Diseases , 1996 .

[16]  Deepak Perumal,et al.  Differential Genome Analyses of Metabolic Enzymes in Pseudomonas aeruginosa for Drug Target Identification , 2007, Silico Biol..

[17]  E. Koonin.  Orthologs, Paralogs, and Evolutionary Genomics 1 , 2005 .

[18]  Hong-Yu Ou,et al.  EG: a database of essential genes , 2004, Nucleic Acids Res..

[19]  B. Murray,et al.  Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. , 2009, The New England journal of medicine.

[20]  A. Camargo,et al.  Specific peptides of casein pancreatic digestion enhance the production of tetanus toxin , 1997, Journal of applied microbiology.

[21]  N. Chandra,et al.  Mycobacterium tuberculosis interactome analysis unravels potential pathways to drug resistance , 2008, BMC Microbiology.

[22]  T. Owa.  [Drug target validation and identification of secondary drug target effects using DNA microarrays]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[23]  Yinduo Ji.  The role of genomics in the discovery of novel targets for antibiotic therapy. , 2002, Pharmacogenomics.

[24]  Brian H. Raphael,et al.  Analysis of genomic differences among Clostridium botulinum type A1 strains , 2010, BMC Genomics.

[25]  Nitesh Kumar Singh,et al.  T-iDT: Tool for Identification of Drug Target in Bacteria and Validation by Mycobacterium Tuberculosis , 2006, Silico Biol..

[26]  K. Mdluli,et al.  Novel targets for tuberculosis drug discovery. , 2006, Current opinion in pharmacology.

[27]  F. Shanahan,et al.  The gut flora as a forgotten organ , 2006, EMBO reports.

[28]  Michael L. Creech,et al.  Integration of biological networks and gene expression data using Cytoscape , 2007, Nature Protocols.

[29]  B. Finlay,et al.  Shifting the balance: antibiotic effects on host–microbiota mutualism , 2011, Nature Reviews Microbiology.

[30]  D. Barh,et al.  In silico subtractive genomics for target identification in human bacterial pathogens , 2011 .

[31]  R. Carman,et al.  Ciprofloxacin at low levels disrupts colonization resistance of human fecal microflora growing in chemostats. , 2004, Regulatory toxicology and pharmacology : RTP.

[32]  Seth Schobel,et al.  Pathema: a clade-specific bioinformatics resource center for pathogen research , 2010, Nucleic Acids Res..

[33]  D. Gurwitz.  Cataloging the interactome of small molecules and the human proteome , 2011 .

[34]  Anirban Dutta,et al.  In Silico Identification of Potential Therapeutic Targets in the Human Pathogen Helicobacter Pylori , 2006, Silico Biol..

[35]  R. Aggarwal,et al.  Subtractive Genomics Approach for in Silico Identification and Characterization of Novel Drug Targets in Neisseria Meningitides Serogroup B , 2009 .

[36]  Guimei Liu,et al.  Protein Interactome Analysis for Countering Pathogen Drug Resistance , 2010, Journal of Computer Science and Technology.

[37]  Michelle Montoya,et al.  β-Barrel membrane protein folding and structure viewed through the lens of α-hemolysin , 2003 .

[38]  M. Peck,et al.  Clostridium botulinum and the safety of minimally heated, chilled foods: an emerging issue? , 2006, Journal of applied microbiology.

[39]  D. Savage.  Microbial ecology of the gastrointestinal tract. , 1977, Annual review of microbiology.

[40]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[41]  V. R. Dowell,et al.  Cultural and physiological characteristics and antimicrobial susceptibility of Clostridium botulinum isolates from foodborne and infant botulism cases , 1980, Journal of clinical microbiology.

[42]  Preeti Gupta,et al.  In silico Identification of Putative Drug Targets from Different Metabolic Pathways of Aeromonas hydrophila , 2008, Silico Biol..

[43]  Yan Lin,et al.  DEG 5.0, a database of essential genes in both prokaryotes and eukaryotes , 2008, Nucleic Acids Res..

[44]  Leonard A. Smith,et al.  Analysis of the Neurotoxin Complex Genes in Clostridium botulinum A1-A4 and B1 Strains: BoNT/A3, /Ba4 and /B1 Clusters Are Located within Plasmids , 2007, PloS one.

[45]  G. Gibson,et al.  An in vitro assessment of the effects of broad-spectrum antibiotics on the human gut microflora and concomitant isolation of a Lactobacillus plantarum with anti-Candida activities. , 2004, Anaerobe.

[46]  F. Guarner,et al.  Gut flora in health and disease , 2003, The Lancet.

[47]  J. Thornton,et al.  Protein Data Resources , 2013 .

[48]  M. Nei,et al.  MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. , 2007, Molecular biology and evolution.

[49]  Cynthia L Sears,et al.  A dynamic partnership: celebrating our gut flora. , 2005, Anaerobe.

[50]  Jue Chen,et al.  Structure, Function, and Evolution of Bacterial ATP-Binding Cassette Systems , 2008, Microbiology and Molecular Biology Reviews.

[51]  Inna Dubchak,et al.  The Genome Portal of the Department of Energy Joint Genome Institute , 2011, Nucleic Acids Res..

[52]  I. Mitov,et al.  Antimicrobial resistance and the management of anaerobic infections , 2007, Expert review of anti-infective therapy.

[53]  J. Lewis,et al.  Analysis of the human gut microbiome and association with disease. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[54]  Jiang Qian,et al.  Systems biology approach to integrative comparative genomics , 2007, Expert review of proteomics.

[55]  L. Beaugerie,et al.  Antibiotic-associated diarrhoea , 2004 .

[56]  Christian von Mering,et al.  STRING 7—recent developments in the integration and prediction of protein interactions , 2006, Nucleic Acids Res..